Rechallenge With Additional Doses of 177 Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs

Clin Nucl Med. 2022 Aug 1;47(8):719-720. doi: 10.1097/RLU.0000000000004239. Epub 2022 Apr 19.


Here, we report a case of a 52-year-old woman with a well-differentiated, metastasized neuroendocrine tumor (NET G1) of the duodenum. Initial imaging with 68 Ga-DOTATOC revealed multiple sites of disease with intense uptake. Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATOC induced partial remission. Treatment was then switched to cold somatostatin analog as a maintenance therapy. After 2 years of follow-up, progressive disease with multiple lesions in the skeleton was noted. Given the initial response to PRRT, a rechallenge with another 2 cycles of PRRT were given, and the patient had an excellent response to treatment, in particular in the skeleton.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Middle Aged
  • Neuroendocrine Tumors* / diagnostic imaging
  • Neuroendocrine Tumors* / drug therapy
  • Neuroendocrine Tumors* / radiotherapy
  • Octreotide / analogs & derivatives
  • Octreotide / therapeutic use
  • Radioisotopes
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Somatostatin
  • Somatostatin* / therapeutic use


  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Somatostatin
  • Octreotide
  • Edotreotide